← All trials
NCT04684108
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2021
- Primary completion
- Sep 15, 2022
- Completion date
- Oct 15, 2022
- First posted
- Dec 24, 2020
- Last posted
- Dec 24, 2020
- Enrollment
- 108
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hangzhou Sumgen Biotech Co., Ltd.Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.